IL267940B2 - Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases - Google Patents
Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseasesInfo
- Publication number
- IL267940B2 IL267940B2 IL267940A IL26794019A IL267940B2 IL 267940 B2 IL267940 B2 IL 267940B2 IL 267940 A IL267940 A IL 267940A IL 26794019 A IL26794019 A IL 26794019A IL 267940 B2 IL267940 B2 IL 267940B2
- Authority
- IL
- Israel
- Prior art keywords
- sema4d
- antagonist antibody
- antigen
- antibody
- binding fragment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762461945P | 2017-02-22 | 2017-02-22 | |
| PCT/US2018/018794 WO2018156509A1 (en) | 2017-02-22 | 2018-02-20 | Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL267940A IL267940A (en) | 2019-09-26 |
| IL267940B1 IL267940B1 (en) | 2024-12-01 |
| IL267940B2 true IL267940B2 (en) | 2025-04-01 |
Family
ID=63253999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL267940A IL267940B2 (en) | 2017-02-22 | 2018-02-20 | Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20190383836A1 (https=) |
| EP (1) | EP3585435A4 (https=) |
| JP (1) | JP7626416B2 (https=) |
| KR (1) | KR102533921B1 (https=) |
| CN (1) | CN110325213A (https=) |
| AU (1) | AU2018225493B2 (https=) |
| BR (1) | BR112019017367A2 (https=) |
| CA (1) | CA3050328A1 (https=) |
| IL (1) | IL267940B2 (https=) |
| MX (1) | MX2019009986A (https=) |
| RU (1) | RU2766341C2 (https=) |
| SG (1) | SG11201906670PA (https=) |
| WO (1) | WO2018156509A1 (https=) |
| ZA (1) | ZA201904431B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2647823T3 (es) | 2009-05-08 | 2017-12-26 | Vaccinex, Inc. | Anticuerpos anti-CD100 y métodos de uso de los mismos |
| BR112014008885B1 (pt) | 2011-10-11 | 2021-02-17 | Vaccinex, Inc | uso de um anticorpo isolado ou fragmento de ligação ao antígeno do mesmo que se liga especificamente à semaforina-4d para diminuir permeabilidade da barreira hematoencefálica (bbb) em um indivíduo com permeabilidade da bbb aumentada e um transtorno neuroinflamatório |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| US10494440B2 (en) * | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| MX377858B (es) | 2013-06-25 | 2025-03-11 | Vaccinex Inc | Combinación de moleculas inhibidoras de semaforina-4d con agentes inmunomoduladores y usos de los mismos. |
| NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| IL262232B2 (en) | 2016-04-22 | 2024-06-01 | Vaccinex Inc | Integral membrane protein display on poxvirus extracellular enveloped virions |
| KR102449406B1 (ko) | 2016-08-02 | 2022-09-29 | 백시넥스 인코포레이티드 | 백시니아 바이러스/진핵 세포에서 폴리뉴클레오티드 라이브러리를 생산하기 위한 개선된 방법 |
| US11597765B2 (en) | 2020-06-25 | 2023-03-07 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules for the treatment of Rett syndrome |
| IL311639A (en) * | 2021-09-27 | 2024-05-01 | Vaccinex Inc | Predictive outcome profile for the use of an anti-semaphorin-4D binding compound for the treatment of neurodegenerative diseases |
| AU2024243083A1 (en) * | 2023-04-03 | 2025-11-20 | Sialbio Co., Ltd. | Pharmaceutical composition for preventing or treating sjogren's syndrome, containing recombinant anti-semaphorin 4d antibody as active ingredient |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013170221A1 (en) * | 2012-05-11 | 2013-11-14 | Vaccinex, Inc. | Use of semaphorin-4d binding molecules to promote neurogenesis following stroke |
| US20150110800A1 (en) * | 2013-10-21 | 2015-04-23 | Vaccinex, Inc. | Use of Semaphorin-4D Binding Molecules for Treating Neurodegenerative Disorders |
| WO2017011746A1 (en) * | 2015-07-15 | 2017-01-19 | Adm Diagnostics, Llc | System and methods for determining a brain condition of a patient sybject to multiple disease states |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0892047A3 (de) * | 1997-07-09 | 2000-03-08 | Hoechst Marion Roussel Deutschland GmbH | Humanes und murines Semaphorin L |
| MX2010012142A (es) * | 2008-05-09 | 2011-04-05 | Abbott Gmbh & Co Kg | Anticuerpos para receptor de productos finales de glucacion avanzada (rage) y usos de los mismos. |
| BR112014008885B1 (pt) * | 2011-10-11 | 2021-02-17 | Vaccinex, Inc | uso de um anticorpo isolado ou fragmento de ligação ao antígeno do mesmo que se liga especificamente à semaforina-4d para diminuir permeabilidade da barreira hematoencefálica (bbb) em um indivíduo com permeabilidade da bbb aumentada e um transtorno neuroinflamatório |
| NZ630881A (en) * | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
-
2018
- 2018-02-20 CN CN201880013208.3A patent/CN110325213A/zh active Pending
- 2018-02-20 WO PCT/US2018/018794 patent/WO2018156509A1/en not_active Ceased
- 2018-02-20 KR KR1020197027287A patent/KR102533921B1/ko active Active
- 2018-02-20 RU RU2019122337A patent/RU2766341C2/ru active
- 2018-02-20 US US16/488,123 patent/US20190383836A1/en not_active Abandoned
- 2018-02-20 IL IL267940A patent/IL267940B2/en unknown
- 2018-02-20 CA CA3050328A patent/CA3050328A1/en active Pending
- 2018-02-20 JP JP2019566047A patent/JP7626416B2/ja active Active
- 2018-02-20 BR BR112019017367-6A patent/BR112019017367A2/pt unknown
- 2018-02-20 AU AU2018225493A patent/AU2018225493B2/en active Active
- 2018-02-20 SG SG11201906670PA patent/SG11201906670PA/en unknown
- 2018-02-20 MX MX2019009986A patent/MX2019009986A/es unknown
- 2018-02-20 EP EP18757318.3A patent/EP3585435A4/en active Pending
-
2019
- 2019-07-05 ZA ZA2019/04431A patent/ZA201904431B/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013170221A1 (en) * | 2012-05-11 | 2013-11-14 | Vaccinex, Inc. | Use of semaphorin-4d binding molecules to promote neurogenesis following stroke |
| US20150110800A1 (en) * | 2013-10-21 | 2015-04-23 | Vaccinex, Inc. | Use of Semaphorin-4D Binding Molecules for Treating Neurodegenerative Disorders |
| WO2015061330A1 (en) * | 2013-10-21 | 2015-04-30 | Vaccinex, Inc. | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| WO2017011746A1 (en) * | 2015-07-15 | 2017-01-19 | Adm Diagnostics, Llc | System and methods for determining a brain condition of a patient sybject to multiple disease states |
Non-Patent Citations (1)
| Title |
|---|
| SMITH, ERNEST S., ET AL., SEMA4D COMPROMISES BLOOD–BRAIN BARRIER, ACTIVATES MICROGLIA, AND INHIBITS REMYELINATION IN NEURODEGENERATIVE DISEASE., 31 December 2015 (2015-12-31) * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7626416B2 (ja) | 2025-02-04 |
| CA3050328A1 (en) | 2018-08-30 |
| IL267940B1 (en) | 2024-12-01 |
| BR112019017367A2 (pt) | 2020-04-14 |
| EP3585435A1 (en) | 2020-01-01 |
| AU2018225493B2 (en) | 2025-03-06 |
| IL267940A (en) | 2019-09-26 |
| NZ755446A (en) | 2025-06-27 |
| RU2019122337A (ru) | 2021-03-23 |
| ZA201904431B (en) | 2024-11-27 |
| RU2766341C2 (ru) | 2022-03-15 |
| RU2019122337A3 (https=) | 2021-06-09 |
| MX2019009986A (es) | 2019-10-14 |
| KR102533921B1 (ko) | 2023-05-17 |
| EP3585435A4 (en) | 2020-12-16 |
| JP2020510845A (ja) | 2020-04-09 |
| WO2018156509A1 (en) | 2018-08-30 |
| KR20190120784A (ko) | 2019-10-24 |
| US20190383836A1 (en) | 2019-12-19 |
| AU2018225493A1 (en) | 2019-08-01 |
| CN110325213A (zh) | 2019-10-11 |
| SG11201906670PA (en) | 2019-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021202095B9 (en) | Use of semaphorin-4D binding molecules for treating neurodegenerative disorders | |
| AU2018225493B2 (en) | Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases |